original ) (raw )An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number
Renata Duchnowska
Oncotarget, 2016
View PDFchevron_right
Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations
Mirjana Rajer
Cancer Biology & Therapy, 2016
View PDFchevron_right
A Phase II Trial of Erlotinib Monotherapy in Pretreated Patients with Advanced Non-small Cell Lung Cancer Who Do Not Possess Active EGFR Mutations: Okayama Lung Cancer Study Group Trial 0705
Katsuyuki Kiura
Journal of Thoracic Oncology, 2010
View PDFchevron_right
Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT)
Peter Vuylsteke
PLOS ONE, 2016
View PDFchevron_right
Erlotinib in previously treated non–small-cell lung cancer
Hung Do
… England Journal of …, 2005
View PDFchevron_right
Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib
Maria Arcila
Clinical Cancer Research, 2011
View PDFchevron_right
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues
Anna Maria Riccardi
Internal and Emergency Medicine, 2007
View PDFchevron_right
Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer: A systematic review
M. Hassan Murad
Annals of Thoracic Medicine, 2013
View PDFchevron_right
Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy
Wilfried Eberhardt
Cancer and Metastasis Reviews, 2010
View PDFchevron_right
Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer
sampurna chatterjee
Oncotarget, 2015
View PDFchevron_right
Approval Summary: Erlotinib Maintenance Therapy of Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Somesh Chattopadhyay
The Oncologist, 2010
View PDFchevron_right
A Phase II Trial of Erlotinib As Front-Line Treatment in Clinically Selected Patients With Non–Small-Cell Lung Cancer
Nikolaos Kentepozidis
Clinical Lung Cancer, 2012
View PDFchevron_right
Evaluation of erlotinib for the treatment of patients with non-small cell lung cancer with epidermal growth factor receptor wild type
Gouji Toyokawa
Oncology Letters, 2017
View PDFchevron_right
Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303)
Tianhong Li
Frontiers in Oncology, 2019
View PDFchevron_right
A prospective, multicenter phase II trial of low-dose erlotinib as maintenance treatment after platinum doublet chemotherapy for advanced non-small cell lung cancer harboring EGFR mutation
Motoyasu Iikura
Chinese clinical oncology, 2016
View PDFchevron_right
Predicting Clinical Benefit in Non-Small-Cell Lung Cancer Patients Treated with Epidermal Growth Factor Tyrosine Kinase Inhibitors
Lukas Amler
Cold Spring Harbor Symposia on Quantitative Biology, 2005
View PDFchevron_right
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer
maricla galetti
Current Pharmaceutical Design, 2012
View PDFchevron_right
Epidermal growth factor receptor (EGFR)—tyrosine kinase inhibitors as a first-line treatment for postoperative recurrent and EGFR-mutated non-small-cell lung cancer
Yojiro Yutaka
Interactive Cardiovascular and Thoracic Surgery, 2021
View PDFchevron_right
New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer
Paul Bunn
Lung Cancer, 2010
View PDFchevron_right
Erlotinib in first-line therapy for non-small cell lung cancer: a prospective phase II study
Sang-we Kim
Anticancer research, 2011
View PDFchevron_right
Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: a case report
Elisabetta Gambale
International medical case reports journal, 2017
View PDFchevron_right
Treatment of advanced non small cell lung cancer with erlotinib. Two clinical cases
Sofia Neves
Revista portuguesa de pneumologia, 2008
View PDFchevron_right
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
Marie Kassapian
The Lancet. Respiratory medicine, 2017
View PDFchevron_right
Making progress in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer by surpassing resistance: third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs)
Giannis Mountzios
Annals of Translational Medicine
View PDFchevron_right
Phase II Trial of Erlotinib for Japanese Patients With Previously Treated Non-small-cell Lung Cancer Harboring EGFR Mutations: Results of Lung Oncology Group in Kyushu (LOGiK0803)
Koichi Takayama
Japanese Journal of Clinical Oncology, 2013
View PDFchevron_right
Erlotinib as a Single Agent in Select Subsets of Patients with Advanced Non–Small-Cell Lung Cancer
gabriela cubillos
Clinical Lung Cancer, 2007
View PDFchevron_right
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial
Ahmed Khalid
The Lancet. Oncology, 2016
View PDFchevron_right
Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?
Jin-Hyuk Choi
The Korean journal of internal medicine, 2017
View PDFchevron_right
A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: Re-evaluation of EGFR gene status (NEJ006/TCOG0903)
Kunihiko Kobayashi
Lung Cancer, 2014
View PDFchevron_right
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
Saulius Cicenas
The Lancet Oncology, 2010
View PDFchevron_right
Epidermal Growth Factor Receptor Inhibition in Mutation-Positive Non-Small-Cell Lung Cancer: Is Afatinib Better or Simply Newer?
Hak Choy , Robert Pirker , Luis Paz-ares
Journal of Clinical Oncology, 2013
View PDFchevron_right